TScan Therapeutics (TCRX) Competitors $1.45 -0.06 (-3.97%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.38%) As of 07/7/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. OLMA, AURA, ATXS, ZYBT, LFCR, BNTC, AVIR, IVA, AARD, and OCGNShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Olema Pharmaceuticals (OLMA), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Zhengye Biotechnology (ZYBT), Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Olema Pharmaceuticals Aura Biosciences Astria Therapeutics Zhengye Biotechnology Lifecore Biomedical Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Ocugen TScan Therapeutics (NASDAQ:TCRX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk. Which has more volatility and risk, TCRX or OLMA? TScan Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Does the media favor TCRX or OLMA? In the previous week, Olema Pharmaceuticals had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 equaled Olema Pharmaceuticals'average media sentiment score. Company Overall Sentiment TScan Therapeutics Neutral Olema Pharmaceuticals Neutral Is TCRX or OLMA more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -2,974.08%. Olema Pharmaceuticals' return on equity of -42.31% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-2,974.08% -55.76% -36.56% Olema Pharmaceuticals N/A -42.31%-38.32% Do insiders & institutionals believe in TCRX or OLMA? 82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 4.4% of TScan Therapeutics shares are held by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, TCRX or OLMA? TScan Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M29.10-$127.50M-$1.09-1.33Olema PharmaceuticalsN/AN/A-$129.47M-$2.01-2.21 Do analysts recommend TCRX or OLMA? TScan Therapeutics presently has a consensus target price of $7.80, indicating a potential upside of 437.93%. Olema Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 450.56%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than TScan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOlema Pharmaceuticals beats TScan Therapeutics on 7 of the 13 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.45M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-1.3320.3027.1920.04Price / Sales29.10250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book0.347.397.925.55Net Income-$127.50M-$55.04M$3.17B$248.49M7 Day Performance1.40%2.51%1.78%4.87%1 Month Performance-19.44%-0.21%1.26%6.63%1 Year Performance-75.09%3.41%33.30%20.38% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics1.9344 of 5 stars$1.45-4.0%$7.80+437.9%-74.6%$85.45M$2.82M-1.33100OLMAOlema Pharmaceuticals1.6948 of 5 stars$4.26-7.8%$24.50+475.1%-58.3%$316.11MN/A-2.1270Positive NewsAURAAura Biosciences1.8621 of 5 stars$6.26-0.3%$22.00+251.4%-12.1%$315.69MN/A-3.2950ATXSAstria Therapeutics1.9262 of 5 stars$5.36-3.8%$30.00+459.7%-31.7%$314.34MN/A-2.8730News CoverageZYBTZhengye BiotechnologyN/A$5.97-9.7%N/AN/A$311.77MN/A0.00278Lockup ExpirationGap DownLFCRLifecore Biomedical1.0034 of 5 stars$8.12-0.9%$8.00-1.5%+68.1%$303.24M$128.26M-5.60690High Trading VolumeBNTCBenitec Biopharma2.1378 of 5 stars$11.70+3.1%$23.83+103.7%+45.2%$297.94M$80K-7.7520News CoverageAnalyst ForecastHigh Trading VolumeAVIRAtea Pharmaceuticals2.3113 of 5 stars$3.60+4.3%$6.00+66.7%+12.0%$295.25MN/A-2.1870High Trading VolumeIVAInventiva2.7319 of 5 stars$3.19+4.6%$10.40+226.0%+2.4%$291.77M$9.95M0.00100AARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018OCGNOcugen0.9653 of 5 stars$0.97-1.4%$6.00+518.3%-43.3%$287.39M$4.05M-5.1180High Trading Volume Related Companies and Tools Related Companies Olema Pharmaceuticals Competitors Aura Biosciences Competitors Astria Therapeutics Competitors Zhengye Biotechnology Competitors Lifecore Biomedical Competitors Benitec Biopharma Competitors Atea Pharmaceuticals Competitors Inventiva Competitors Aardvark Therapeutics Competitors Ocugen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts